Guided Therapeutics (GTHP) Non-Current Deferred Tax Liability (2013 - 2014)
Guided Therapeutics (GTHP) reported Non-Current Deferred Tax Liability of $26.0 million for Q4 2014, up 14.32% on a YoY basis from $22.7 million in Q4 2013, and up 14.32% sequentially from $22.7 million in Q4 2013.
Guided Therapeutics (GTHP) Non-Current Deferred Tax Liability (2013 - 2014) Analysis & Trends
Guided Therapeutics (GTHP) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $26.0 million in Q4 2014.
- For the quarter ending Q4 2014, Non-Current Deferred Tax Liability rose 14.32% year-over-year to $26.0 million; the trailing twelve-month figure through Dec 2014 stood at $26.0 million (up 14.32% YoY), and the FY2014 full-year result was $26.0 million, up 14.32% from the prior year.
- Non-Current Deferred Tax Liability grew to $26.0 million in Q4 2014, from $22.7 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $26.0 million in Q4 2014 to a low of $22.7 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 25.99 Mn |
| Dec 31, 2014 | 25.99 Mn |
| Dec 31, 2013 | 22.74 Mn |
| Dec 31, 2013 | 22.74 Mn |